Establishment of a Gonococcal Antimicrobial Surveillance Programme, in Accordance With World Health Organization Standards, in Côte d'Ivoire, Western Africa, 2014–2017

Background Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is compromising the treatment of gonorrhea globally. Recent AMR data are extremely limited in Africa, and mainly totally lacking in Western Africa, including Côte d'Ivoire. This study (i) established a quality-assured gonococcal antimicrobial surveillance program, according to World Health Organization quality criteria, (ii) investigated the AMR to 8 therapeutic antimicrobials in gonococcal isolates from 2014 to 2017, and (iii) provided evidence for updating the National Sexually Transmitted Disease Syndromic Management Guidelines in Côte d'Ivoire. Methods During 2014 to 2017, gonococcal isolates were obtained from sexually active symptomatic or asymptomatic males and females in 14 sites in Côte d'Ivoire. It was a special focus on symptomatic males, and their sexual partners, due to the higher culture positivity rates in symptomatic males. Patient metadata were collected, including age, gender, sexual orientation, and symptoms. Minimum inhibitory concentrations of 8 antimicrobials were determined by Etest and interpreted using European Committee on Antimicrobial Susceptibility Testing breakpoints. &bgr;-lactamase production was detected using cefinase disks. Results The level of resistance, examining 212 gonococcal isolates, was as follows: 84.9% to tetracycline, 68.9% to benzylpenicillin, 62.7% to ciprofloxacin, 6.1% to azithromycin, and 1.4% to gentamicin. All isolates were susceptible to ceftriaxone, cefixime and spectinomycin. Conclusions We provide the first gonococcal AMR data, quality assured according to World Health Organization standards, from Côte d'Ivoire since more than 20 years. The high ciprofloxacin resistance, which informed a revision of the national syndromic management guideline during study, and relatively high resistance to azithromycin demand an improved gonococcal antimicrobial surveillance program and increased awareness when prescribing treatment in Côte d'Ivoire.

[1]  M. Unemo,et al.  Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018 , 2018, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  Monica Lahra,et al.  Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin. , 2018, The Lancet. Infectious diseases.

[3]  W. Demczuk,et al.  Cooperative Recognition of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain , 2018, Emerging infectious diseases.

[4]  A. Amato-Gauci,et al.  Overall Low Extended-Spectrum Cephalosporin Resistance but high Azithromycin Resistance in Neisseria gonorrhoeae in 24 European Countries, 2015 , 2017, BMC Infectious Diseases.

[5]  Suzanna C Francis,et al.  Sexually transmitted infections: challenges ahead. , 2017, The Lancet. Infectious diseases.

[6]  M. Unemo,et al.  Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action , 2017, PLoS medicine.

[7]  M. Unemo,et al.  Antimicrobial susceptibility in Neisseria gonorrhoeae isolates from five sentinel surveillance sites in Zimbabwe, 2015–2016 , 2017, Sexually Transmitted Infections.

[8]  L. Sánchez-Busó,et al.  The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization. , 2016, The Journal of antimicrobial chemotherapy.

[9]  K. Holmes,et al.  Neisseria gonorrhoeae Antimicrobial Susceptibility Surveillance - The Gonococcal Isolate Surveillance Project, 27 Sites, United States, 2014. , 2016, Morbidity and mortality weekly report. Surveillance summaries.

[10]  M. Unemo,et al.  Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. , 2016, The New England journal of medicine.

[11]  Marleen Temmerman,et al.  Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting , 2015, PloS one.

[12]  Magnus Unemo,et al.  Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge , 2015, BMC Infectious Diseases.

[13]  M. Unemo,et al.  Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future , 2014, Clinical Microbiology Reviews.

[14]  H. Grosskurth,et al.  High Prevalence of Ciprofloxacin-Resistant Gonorrhea Among Female Sex Workers in Kampala, Uganda (2008–2009) , 2014, Sexually transmitted diseases.

[15]  M. Unemo,et al.  Mitigating the emergence and spread of multidrug- and extensively drug-resistant gonorrhea: is there sufficient support in resource-poor settings in Africa? , 2014, Sexually transmitted diseases.

[16]  D. Lewis Global resistance of Neisseria gonorrhoeae: when theory becomes reality , 2014, Current opinion in infectious diseases.

[17]  M. Fonkoua,et al.  Gonococcal antimicrobial resistance: perspectives from the African region , 2013, Sexually Transmitted Infections.

[18]  M. Unemo,et al.  Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. , 2013, The Journal of antimicrobial chemotherapy.

[19]  F. Martinson,et al.  Neisseria gonorrhoeae Antimicrobial Susceptibility in Lilongwe, Malawi, 2007 , 2010, Sexually transmitted diseases.

[20]  M. Unemo,et al.  Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. , 2009, The Journal of antimicrobial chemotherapy.

[21]  P. Ghys,et al.  Increasing Resistance of Neisseria gonorrhoeae in West and Central Africa: Consequences on Therapy of Gonococcal Infection , 1997, Sexually transmitted diseases.